V1
笨熊是一家 声望 3
生物安全
Mortality within 30days following systemic anti-cancer therapy, a review of all cases over a 4year period in a tertiary cancer centre
作者:, J. Hasan
摘要:Abstract Background The national confidential enquiry into patient outcomes and death (NCEPOD) set important benchmarks in assessing the quality of care received by patients dying within 30 days of systemic anticancer therapy (SACT). Monthly morbidity and mortality audits conducted to recommendations in the NCEPOD were commenced at the Christie NHS Foundation Trust in 2009, specifically to assess and improve patient outcomes. Methods We evaluated the outcomes of patients who died within 30 days of SACT over a 4 year period 2009–2013. We collated audit findings to determine the number of treatment related deaths, clinical characteristics of patients, causes of death and quality of care received. We examined the benefit of the audit in decreasing 30 day mortality during the 4 years and considered factors that may be associated with an increased risk of SACT related death. Results A total of 31,183 patients were treated at the Christie from 2009 to 2013. Of these 4% died within 30 days of SACT. Death was treatment related in 11%. The decision to treat with SACT was appropriate in 87% of but there was room for improvement in care in 24%. Mortality decreased over the 4 years. Possible factors associated with 30 day mortality post SACT included performance status ⩾2, presence of comorbidities, treatment type and treatment setting. Conclusions We demonstrated that our audit process is feasible and robust. Further areas of research to determine predictive scores for patient treatment selection and improve outcomes were highlighted and are ongoing.
关键词:
论文方向:
发表期刊:European Journal of Cancer Volume 51, Issue 2
发表时间:Sat Jan 31 00:00:00 CST 2015
数字识别码:10.1016/j.ejca.2014.11.011
是否作者本人:

版权及免责声明:

本网站所有论文文件均系用户自行上传或提供,本网站对其内容准确性及合法性概不负责,亦不承担任何法律责任。论文版权归原作者及原出处所有。

如您发现网站其他用户上传的论文有侵犯您的姓名权、隐私权、著作权或其他合法权益现象的,请及时与本网站联系并附加相关权利证明文件,以便本网站及时作出处理,维护您的合法权益。

本网站拥有对此声明的最终解释权。

全部评论 ( 0 )

发评论
5.0/10分

0人评分